X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Panacea Biotech with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs TEVA PHARMA (Israel) - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PANACEA BIOTECH   TEVA PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
TEVA PHARMA
Dec-13
PANACEA BIOTECH/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1492,665-   
Low Rs822,315-   
Sales per share (Unadj.) Rs84.11,529.5-  
Earnings per share (Unadj.) Rs-18.395.5-  
Cash flow per share (Unadj.) Rs-6.7219.2-  
Dividends per share (Unadj.) Rs083.64-  
Dividend yield (eoy) %03.4 0.0%  
Book value per share (Unadj.) Rs83.71,699.0-  
Shares outstanding (eoy) m61.25848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.41.6 84.3%   
Avg P/E ratio x-6.326.1 -24.2%  
P/CF ratio (eoy) x-17.211.4 -151.8%  
Price / Book Value ratio x1.41.5 94.1%  
Dividend payout %087.5 0.0%   
Avg Mkt Cap Rs m7,0742,111,647 0.3%   
No. of employees `0002.844.9 6.1%   
Total wages/salary Rs m1,4490-   
Avg. sales/employee Rs Th1,874.128,858.6 6.5%   
Avg. wages/employee Rs Th527.00-   
Avg. net profit/employee Rs Th-407.71,802.8 -22.6%   
INCOME DATA
Net Sales Rs m5,1541,297,049 0.4%  
Other income Rs m1000-   
Total revenues Rs m5,2541,297,049 0.4%   
Gross profit Rs m-766355,198 -0.2%  
Depreciation Rs m711104,842 0.7%   
Interest Rs m1,50325,476 5.9%   
Profit before tax Rs m-2,881224,880 -1.3%   
Minority Interest Rs m111,022 1.1%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-147,621 -1.2%   
Tax Rs m17-2,746 -0.6%   
Profit after tax Rs m-1,12181,026 -1.4%  
Gross profit margin %-14.927.4 -54.3%  
Effective tax rate %-0.6-1.2 47.8%   
Net profit margin %-21.86.2 -348.3%  
BALANCE SHEET DATA
Current assets Rs m3,810876,022 0.4%   
Current liabilities Rs m8,365763,965 1.1%   
Net working cap to sales %-88.48.6 -1,023.1%  
Current ratio x0.51.1 39.7%  
Inventory Days Days15691 171.5%  
Debtors Days Days6796 70.1%  
Net fixed assets Rs m14,480423,645 3.4%   
Share capital Rs m613,193 1.9%   
"Free" reserves Rs m9030-   
Net worth Rs m5,1271,440,775 0.4%   
Long term debt Rs m5,832663,210 0.9%   
Total assets Rs m19,4332,964,172 0.7%  
Interest coverage x-0.99.8 -9.3%   
Debt to equity ratio x1.10.5 247.1%  
Sales to assets ratio x0.30.4 60.6%   
Return on assets %2.03.6 54.7%  
Return on equity %-21.95.6 -388.9%  
Return on capital %3.64.9 73.7%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Net fx Rs m5970-   
CASH FLOW
From Operations Rs m599206,682 0.3%  
From Investments Rs m-438-73,236 0.6%  
From Financial Activity Rs m-303-247,930 0.1%  
Net Cashflow Rs m-141-114,483 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 63.85 Rs / USD

Compare PANACEA BIOTECH With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare PANACEA BIOTECH With: SUN PHARMA  NOVARTIS  SANOFI INDIA  PLETHICO PHARMA  VENUS REMEDIES  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jan 22, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - UNICHEM LAB COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS